Meeting
2014 ASCO Annual Meeting
Enobosarm: A targeted therapy for metastatic, androgen receptor positive, breast cancer.
Authors
Beth Overmoyer
Dana-Farber Cancer Institute, Boston, MA
Beth Overmoyer , Pedro Sanz-Altamira , Ryan P. Taylor , Michael L. Hancock , James T. Dalton , Mary Ann Johnston , Mitchell S. Steiner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT01616758
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 568)
DOI
10.1200/jco.2014.32.15_suppl.568
Abstract #
568
Poster Bd #
32
Abstract Disclosures
Similar Posters
Poster
2014 Breast Cancer Symposium
The effect of trastuzumab therapy on clinical benefit from fulvestrant treatment for metastatic estrogen receptor-positive breast cancer patients.
First Author: Mahmoud Charif
Poster
2023 ASCO Annual Meeting
Negative estrogen receptor expression assessed by 18F-FES PET in metastatic breast cancer with ER-positive primary tumor.
First Author: Biyun Wang
Poster
2022 ASCO Genitourinary Cancers Symposium
A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naïve prostate cancer (mHNPC): ZZFIRST.
First Author: Joaquin Mateo
Poster
2017 ASCO Annual Meeting
Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study.
First Author: Geoffrey John Lindeman